Search This Website

Friday, January 1, 2021

Coronavirus: The WHO first approved the vaccine for emergency use

Coronavirus: The WHO first approved the vaccine for emergency use

The World Health Organization has approved the Pfizer biotech vaccine for emergency use. This is the first time a vaccine has been approved by the WHO since the outbreak of the coronavirus.

Coronavirus: The WHO first approved the vaccine for emergency use

The WHO's decision has opened the door to vaccines for other countries and will soon allow its import and distribution.

Let me tell you that Britain first approved the emergency use of this vaccine on December 8. The United States, Canada, and the European Union later approved the vaccine.

The World Health Organization said the Pfizer-Biotech vaccine was the first vaccine to be approved for emergency use by the organization following the outbreak of the coronavirus. "This is a positive step towards ensuring global access to the corona vaccine," said Mariengela Simao, a senior WHO official.

The WHO reviewed data on the safety, efficacy, and quality of the Pfizer vaccine from experts themselves and around the world, and evaluated its benefits and risks. "The review shows that the vaccine meets the safety and efficacy criteria set by the WHO," he said.

 India has marked the New Year's Day by giving its first-ever approval to a coronavirus vaccine.

A government-appointed expert panel on Friday cleared the decks for emergency use of the vaccine developed by AstraZeneca and Oxford University, sources said. The final nod will now come from the Drugs Controller General of India (DCGI).

The Serum Institute of India, the local manufacturer of the vaccine, has already stockpiled nearly 50 million doses and a majority of them will be used in India.

One of the sources said the shots could start to be transported from cold storage to Indian states as early as Saturday.

Sources told Reuters that the Central Drugs Standard Control Organization (CDSCO), whose experts were meeting for the second time this week, could also approve a vaccine locally developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

The government said on Wednesday that Pfizer Inc had sought more time to present data for emergency authorization of a vaccine it has developed with Germany's BioNTech.

Earlier today, the Serum Institute had given a presentation before the 10-member Subject Expert Committee of the drug regulator for the approval of its coronavirus vaccine.

The UK-based Oxford vaccine has been considered as the frontrunner in India's quest for vaccines.


ગુજરાતી માં સમગ્ર ન્યૂઝ વાંચવા અહી ક્લિક કરો 


Unlike vaccines from other candidates like Pfizer and Moderna, Covishield does not have to be stored in freezing conditions and requires storage at domestic fridge temperatures (2 to 8 degrees Celsius).

The vaccine also holds a cost advantage over others and is likely to be priced well under Rs 1,000 for two mandatory dosages, both the company and government sources have indicated.

No comments:

Post a Comment

Featured Posts